Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The purinergic receptor P2Y family comprises a group of G protein-coupled receptors (GPCRs) activated by extracellular nucleotides, including ATP, ADP, UTP, UDP, and UDP-glucose. They play key roles in purinergic signaling, regulating diverse physiological processes through different subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14) that vary in ligand specificity, G protein coupling, tissue distribution, and function. These receptors are involved in platelet aggregation, neuronal activity modulation, microglial function, inflammation regulation, and potentially neurodegenerative diseases. Drugs targeting specific P2Y subtypes, such as antiplatelet agents targeting P2Y12, have been developed for clinical use.
Agonist or antagonist at specific P2Y receptor subtypes, modulating downstream signaling pathways such as PLC activation, IP3/DAG production, Ca2+ release, adenylyl cyclase inhibition, and cAMP reduction.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Purinergic Receptor P2Y Family (P2Y).